Results 101 to 110 of about 7,444 (141)

The role of systemic inflammation in hepatic encephalopathy: advances in inflammatory mechanisms, prevention and treatment research. [PDF]

Ann Med
Wang W, Wen Y.
europepmc   +1 more source

<i>In vitro</i> study of ethanol production, ethanol tolerance, and antimicrobial susceptibility of gut microbes associated with liver diseases. [PDF]

Gut Microbes Rep
Idrissa Abdoulaye A, Mbaye B, Magdy Wasfy R, Carmarans L, Beye M, Andrieu C, Bakour S, Hamieh A, Armstrong N, Borentain P, Bittar F, Ranque S, Rolain JM, Dubourg G, Lagier JC, Tidjani Alou M, Gerolami R, Million M.   +17 more
europepmc   +1 more source

Relationship between small intestinal bacterial overgrowth and irritable bowel syndrome and the efficacy of rifaximin intervention: a systematic review and meta-analysis. [PDF]

Front Microbiol
Lu H.
europepmc   +1 more source

Rifaximin-Induced Rhabdomyolysis. [PDF]

Cureus
Acheampong S, Udoyeh C, Darko P, Omeludike EK.   +3 more
europepmc   +1 more source

Rifaximin Use Is Associated With Prognosis and Recurrence Patterns in Spontaneous Bacterial Peritonitis: Exploratory Insights Into the Oral-Gut-Hepatic Axis. [PDF]

JGH Open
Uchida Y, Soma N, Yamada S, Tsuji S, Ando S, Sugawara K, Nakao M, Nakayama N, Imai Y, Mizuno S, Mochida S.   +10 more
europepmc   +1 more source

Secondary Prophylaxis of Hepatic encephalopathy in Liver cirrhosis: Rifixamine plus Probiotics vs. Rifixamine alone. [PDF]

Pak J Med Sci
Shahzad K, Sarwar S, Saeed S, Umer A.
europepmc   +1 more source

Understanding Hepatic Encephalopathy: Patient Knowledge, Adherence, and Barriers to Care in Cirrhosis. [PDF]

Cureus
Albusta N, Ali A, Alrahma H.
europepmc   +1 more source

Synergistic effect of the rifaximin-berberine combination against <i>Klebsiella pneumoniae</i>: RfaH targeting supported by MD simulation. [PDF]

Biomol Biomed
Ashraf A, Khan MA, Choudhury A, Kumari S, Alotaibi BS, Noor S, Adnan M, Hassan MI.   +7 more
europepmc   +1 more source

Rifaximin reduces rehospitalization risk in patients with cirrhosis and overt hepatic encephalopathy. [PDF]

Hepatol Commun
Jesudian AB, Gagnon-Sanschagrin P, Bungay R, Easson K, Bellefleur R, Guérin A, Shah SK, Olujohungbe O.   +7 more
europepmc   +1 more source

Risk-stratified pharmacologic strategies for secondary prevention after acute diverticulitis: an exploratory narrative review and research framework. [PDF]

Front Surg
Schiano di Visconte M, Sarnari S, Lo Monaco D, Brillantino A, Marano L, Talento P, Guttadauro A.   +6 more
europepmc   +1 more source